Bayer sales and marketing update

The U.K.’s NICE issued draft guidance recommending Xofigo radium-223 dichloride from Bayer to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no

Read the full 257 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE